1. Background {#sec119522}
=============

Quinolones, especially novel quinolones (6-fluoroquinolones), are synthetic broad-spectrum antibacterial agents that compete with beta-lactam. Macrolide antibacterial agents have been used to treat serious infections ([@A16217R1]). Since the detection of plasmid-mediated quinolone resistance (PMQR) in *Klebsiella pneumoniae* strains isolated from clinical specimens from the USA in the late 1990s ([@A16217R2], [@A16217R3]), three PMQR mechanisms have been discovered. One PMQR mechanism has been reported worldwide in various enterobacterial species in the presence of the *qnr* genes ([@A16217R4]). Another mechanism is related to the *AAC (6´)-Ib-cr* gene, which is responsible for decreasing susceptibility to quinolones by N-acetylation of a piperazinyl amine substituent of some fluoroquinolones ([@A16217R5]). A third PMQR mechanism, which is based on a quinolone efflux pump protein, QepA, has been reported recently ([@A16217R6]).

*Qnr* is a member of the pentapeptide repeat family that protects DNA gyrase and topoisomerase IV from quinolone inhibition ([@A16217R7]). Extended-spectrum beta lactamase (ESBL) strains are often plasmid-mediated, and most of these enzymes belong to the *TEM* or *SHV* families ([@A16217R8]) that have been reported in many countries ([@A16217R9]). In recent studies, a significant relationship was observed between quinolone resistance and the latest cephalosporin antibacterial agents ([@A16217R10]-[@A16217R13]). The association of *qnr* and ESBL production genes or AmpC-type β lactamase has been observed ([@A16217R14]). Furthermore, many studies have demonstrated that plasmids harboring *qnr* may also carry other genes that respond to ESBL-producing strains ([@A16217R15], [@A16217R16]).

2. Objectives {#sec119523}
=============

Considering the worldwide spread of the *qnr* gene, especially in hospitalized patients, and the fact that few studies have focused on *qnr* genes in ESBL-producing *Escherichia coli* isolates in Iran, the aim of this study was to determine the frequency of three *qnr* gene types in ESBL-producing and non-ESBL-producing *E. coli* clinical isolates at the Imam Reza Hospital in Mashhad, Iran.

3. Materials and Methods {#sec119530}
========================

3.1. Bacterial Isolates {#sec119524}
-----------------------

The descriptive cross-sectional study included 200 *E. coli* clinical isolates collected from outpatients and hospitalized patients in Imam Reza Hospital from May 2011 to July 2012. We classiﬁed the patients as hospitalized if they were admitted to the hospital and stayed for a minimum of 24 hours. We classified the patients as outpatients if they were not hospitalized for more than 24 hours but visited a hospital, clinic, or associated facility for diagnosis or treatment ([@A16217R17]). The sample size was calculated based on level of confidence, expected prevalence, and precision (corresponding to effect size) ([@A16217R18]). The research was approved by the ethics committee of the faculty of medicine in Mashhad. Clinical samples, including urine, blood, wound cultures, and CSF, were processed in this study. Specimens were collected by a laboratory technician and immediately transferred to the microbiology department of Mashhad University of Medical Sciences in sterile screw cap tubes containing 5 mL of tryptic soy broth (Sigma; USA). Prior to specimen collection, criteria such as previous antimicrobial therapy, immune suppression, and presence of bacteremia because of other pathogens before and after colonization by *E. coli* were taken into consideration. Standard biochemical tests were used to detect *E. coli* strains ([@A16217R19]).

3.2. Antimicrobial Susceptibility Testing {#sec119525}
-----------------------------------------

Susceptibility tests for ciprofloxacin, ceftazidime, cefotaxime, and cefpodoxime were performed for ESBL- and non-ESBL-producing *E. coli* by using the standard disc diffusion test according to the clinical and laboratory standards institute guidelines ([@A16217R20]). Isolated *E. coli* were cultured on Muller-Hinton agar. Ciprofloxacin (5 µg), ceftazidime (30 µg), cefotaxime (30 µg), and cefpodoxime (10 µg) disks (Mast, UK) were placed on the inoculated plate and incubated at 35°C for 16 - 20 h. Drug resistance was recognized according to their zone sizes compared with the break point announced by the clinical and laboratory standards institute for *Enterobacteriaceae* ([@A16217R20]).

3.3. Phenotypic Confirmatory Test {#sec119526}
---------------------------------

The combination disc method was used for detecting ESBL strains. Bacteria were cultured on a Muller-Hinton agar plate, and ceftazidime (30 μg) versus ceftazidime/clavulanate (30/10 μg), cefotaxime (30 μg) versus cefotaxime/clavulanate (30/10 μg), and cefpodoxime (10 μg) versus cefpodoxime/clavulanate (30/10 μg) (Mast Diagnostics, UK) were tested. Antibiotic disks were placed in media at a distance of 20 - 30 mm from other disks. After 18 - 24 hours incubation at 37°C, ESBL-producing organisms were detected by observation of a zone diameter increase of at least 5 mm around antibacterial agents in combination with clavulanic acid ([@A16217R20]). The reference strain *Klebsiella pneumonia* ATCC 700603 was used as an ESBL-positive control ([@A16217R10]).

3.4. Multiplex PCR for TEM and SHV Genes {#sec119527}
----------------------------------------

*Escherichia coli* isolate DNA was extracted by the simple boiling method. *E. coli* isolates were cultured on MacConkey agar (Merck, Germany) and incubated at 37°C. After 24 hours, 1 - 5 colonies were suspended in TE buffer, and suspensions were boiled for 10 minutes ([@A16217R21]). PCR was performed using gene-specific primers to detect two ESBL-encoding gene types (*bla*~*SHV*~ and *bla*~*TEM*~) ([@A16217R21]). The following conditions were used: 2 minutes at 95°C, followed by 35 cycles of 1 minute at 91°C, 30 seconds at 52°C, and 45 seconds at 72°C, and 1 minute at 72°C and 5 minutes at 72°C for the final extension ([@A16217R19]). Each 25 µL of reaction mixture contained 2.5 µL of 10 × PCR Buffer, 1.5 mM MgCl~2~ (25 mM), 320 µM dNTPs (10 mM), 500 nM of each primer (10 pm/µL), 50 ng template DNA, and 0.5 U/µl Taq DNA polymerase (CinnaGen, Iran). Pure water was added for a final volume of 25 µl. *K. pneumoniae* ATCC 7881 containing the *bla*~*SHV*~ and *bla*~*TEM*~ genes (Pasteur Institute of Iran, Tehran) was used as a positive control.

3.5. PCR for qnr Genes {#sec119528}
----------------------

The PCR method was performed for three *qnr* gene types (*qnrA*, *qnrB*, and *qnrS*) under the following conditions: 5 minutes at 94°C, followed by 35 cycles of 30 seconds at 94°C, 45 seconds at 50°C, and 45 seconds at 72°C and 5 minutes at 72°C for the final extension. Primers specific to *qnr* genes were used in this study ([@A16217R12]). PCR was performed in 25 µL volumes, with each reaction mixture containing 2.5 µL of 10 × PCR Buffer, 1.5 mM MgCl~2~ (25 mM), 200 µM dNTPs (10 mM), 0.5 µM of each primer (10 pm/µL), 50 ng template DNA, and 1 U/µL of Taq DNA polymerase. Pure water was added for a final volume of 25 µL. All PCR amplifications were performed in duplicate. Standard positive strains for the *qnrA*, *qnrB*, and *qnrS* genes were not available in this study; therefore, in addition to checking the size of the amplicons, negative strains were repeated twice for accuracy. Additionally, PCR products were sequenced (one isolate for each gene) and analyzed with the basic local alignment search tool algorithm (http://blast.ncbi.nlm.nih.gov/Blast.cgi).

3.6. Statistical Analysis {#sec119529}
-------------------------

The Chi-square test was performed to compare variables. A P value ≤ 0.05 was considered significant.

4. Results {#sec119531}
==========

Two hundred *E. coli* isolates were tested from 84 outpatients and 116 hospitalized patients at the Imam Reza Hospital in Mashhad, Iran from May 2011 to July 2012. Overall, 61% of the hospitalized patients were male and 39% were female. The average age of the patients was 55 years ± 0.8 years. The phenotypic confirmatory test identified 85 (42.5%) isolates as ESBL-producing *E. coli*. The greatest proportion \[72.9% (62 of 85)\] of ESBL-producing isolates was isolated from urine samples, followed by 8.23% (7 of 85) from wound samples, 8.23% (7 of 85) from blood samples, 3.52 (3 of 85) from ascitic fluid samples, and 2.35% (2 of 85) from secretion samples. The remaining 4.7% (4 of 85) of isolates were isolated from CSF, pleural fluid, ear, and nose secretion samples.

*bla*~*TEM*~ was present in 65 (76.47%) of 85 phenotypic ESBL-producing isolates, while 23 (27%) ESBL-producing isolates were positive for the *bla*~*SHV*~ gene. Some ESBL-producing isolates possessed both the *bla*~*TEM*~ and *bla*~*SHV*~ genes. PCR amplification results of the *SHV* and *TEM* genes are displayed in [Figure 1](#fig22799){ref-type="fig"}. *qnrA*, *qnrB,* and *qnrS* genes were prevalent in 31.5% (63 of 200), 17% (34 of 200), and 7% (14 of 200) of *E. coli isolates,* respectively. PCR amplification results of the *qnr* genes are displayed in [Figure 2](#fig22800){ref-type="fig"}. The results are summarized in [Table 1](#tbl30842){ref-type="table"}.

![*bla* Gene PCR Product Electrophoresis on a 1% Agarose Gel\
Lane 1 displays a 471 bp fragment of the *SHV* gene. Lane 5 displays an 861 bp fragment of the *TEM* gene. Lanes 2 and 3 are positive for *SHV* and *TEM*. Lane M represents the 100 bp DNA ladder. Lane NC: negative control. Lane PC: positive control.](jjm-08-12-16217-g001){#fig22799}

![*qnr* Gene PCR Product Electrophoresis on a 1% Agarose Gel\
Lanes 1 and 2 display a 516 bp fragment of the *qnrA* gene. Lane 4 displays a 469 bp fragment of the *qnrB* gene. Lane 5 displays a 417 bp fragment of the *qnrS* gene. Lane M represents the 100 bp DNA ladder. Lane NC: negative control. Lane PC: positive control.](jjm-08-12-16217-g002){#fig22800}

###### *qnrA*, *qnrB,* and *qnrS* Gene Frequencies in Isolated *E. coli*^[a](#fn31236){ref-type="table-fn"}^

  *qnr*    ESBL        
  -------- ----------- -----------
  *qnrA*   29 (34.1)   34 (29.6)
  *qnrB*   15 (17.6)   19 (16.5)
  *qnrS*   9 (10.6)    5 (4.3)

^a^Values are presented as No. (%).

In one of the isolates, both *qnr* genes (*qnrA* and *qnrS*) and both ESBL genes (*bla*~*TEM*~ and *bla*~*SHV*~) were detected, while 32 isolates contained at least one ESBL and one *qnr* gene. The disk diffusion method indicated that 86 (43%) isolates were resistant to ciprofloxacin. Additionally, 93 (46.5%), 104 (52%), and 105 (52.5%) isolates were resistant to ceftazidime, cefotaxime, and cefpodoxime, respectively. Sixty-eight (34%) isolates were resistant to ciprofloxacin and produced ESBL. ESBL strain frequencies in hospitalized patients and outpatients were 70.6% and 29.4%, respectively. *bla*~*TEM*~ and *bla*~*SHV*~ gene frequencies were 68.2% and 66.7%, respectively, in hospitalized patients. *qnrA*, *qnrB*, and *qnrS* gene frequencies were 63 (31%), 34 (17%), and 14 (7%), respectively. *qnr* (A, B, S) frequencies in hospitalized patients and outpatients are summarized in [Figure 3](#fig22801){ref-type="fig"}.

![The distribution of Non-ESBL- and ESBL-Producers and *bla*~*TEM*~, *bla*~*SHV*~, *qnrA,* *qnrB*, and *qnrS* Frequencies in *E. coli* Strains Isolated From Outpatients and Hospitalized Patients](jjm-08-12-16217-i001){#fig22801}

5. Discussion {#sec119532}
=============

Plasmid-mediated genes, such as *qnr*, may facilitate the spread and increase the prevalence of quinolone-resistant strains. To date, *qnr* genes have been widely detected in Southern and Eastern Asia, North and South America, and Europe. The present study demonstrated a high prevalence of *qnr* genes among ESBL-producing *E. coli* isolates collected from the Imam Reza hospital in Mashhad, Iran. The high prevalence of *qnr* genes among ESBL-producing enterobacterial species has been previously reported. Our study revealed that the *qnr* gene could co-exist with the *bla*~*TEM*~ and *bla*~*SHV*~ alleles. PMQR strains, which carry the *qnr* gene, can transfer low-level quinolone resistance ([@A16217R22]). Various studies have indicated that most enzymes from ESBL-producing organisms can be horizontally transmitted by the same plasmids harboring *qnr* genes ([@A16217R22], [@A16217R23]).

In this study, 85 (42.5%) of 200 isolates were recognized as ESBL-producing *E. coli*. Furthermore, the prevalence of ESBL-producing *E. coli* was high, especially in hospitalized patients. More than 70% of ESBL-producing organisms were *bla*~*TEM*~*-* and/or *bla*~*SHV*~*-*positive. In a study conducted in Mashhad, Iran, the prevalence of ESBL-producing *E. coli* and *K. pneumoniae* were 15.62% and 20%, respectively ([@A16217R21]). In contrast, our results suggested that there is evidence of a higher prevalence of ESBL-producers. In 2007, in a study in Mashhad, the rate of ESBL-producing *E. coli* was reported to be 57.5%, which was higher than the rate of ESBL-producers in our study ([@A16217R24]). Our molecular findings indicated that *bla*~*TEM*~ was more prevalent than *bla*~*SHV*~. This molecular pattern was similar to previous studies by Pakzad et al. and Masjedian Jazi et al. ([@A16217R10], [@A16217R25]). In contrast, a study investigating the molecular pattern of ESBL-producing *K. pneumoniae* in Kashan reported that *SHV1* was the most frequent genotype ([@A16217R26]).

In the present study, the most prevalent gene among all isolates was *qnrA,* followed by *qnrB* and *qnrS*. In a similar study in Iran, *qnrA* and *qnrB* were recognized as the dominant genes. This finding is in agreement with our results ([@A16217R10]). To our knowledge, there have not been any previous reports of the *qnrS* gene in ESBL-producing organisms in Iran. *qnr* gene frequency in ESBL-producing *E. coli* varies by country. In Egypt, *qnrB1, qnrA1, and qnrS* were reported in 23.3%, 16.6%, and 16.6%, respectively, of 30 ESBL-producing *E. coli* isolates ([@A16217R27]). In Morocco, among 39 ESBL-producing *Enterobacteriaceae* isolates, 14 (36%) were positive for *qnr* (*qnrA:* 10%; *qnrB:* 23%; and *qnrS:* 3%) ([@A16217R28]). In a study in Kuwait, low prevalence was reported for *qnr* determinants in ESBL-producing enterobacterial isolates. In this study, among 64 ESBL-producing *Enterobacteriaceae*, only two *Enterobacter cloacae* and one *Citrobacter freundii* isolates were positive for the *qnrB*-like gene, whereas no *qnrA*-like or *qnrS*-like genes were detected ([@A16217R29]). In the USA, among 313 ceftazidime-resistant *Enterobacteriaceae* isolates, 23% were positive for either *qnrA* or *qnrB,* while *qnrS* was absent ([@A16217R12]).

We found that in some of our isolates both *qnr* and ESBL genes were detected. There are many reports on *qnr* and ESBL gene insertion into the same plasmid that are consistent with our findings ([@A16217R15], [@A16217R30]). In Korea, *qnrB* (subtype *B4*), *SHV*~*12*~, and *DHA-1* were the most frequent genes in *K. pneumoniae*. Korean researchers found that *SHV-12*and *DHA-*1 were co-produced with *qnrA1* and *qnrB4* ([@A16217R31]). In a Taiwanese hospital, all *qnr*-positive ESBL-producing *E. cloacae* isolates possessed the *bla SHV-12* and *qnrB2*-like genes ([@A16217R32]). In this study, we found that *TEM* was the most prevalent *ESBL* gene and was co-produced with *qnrA* as dominant *qnr* determinants. Our findings revealed that some ciprofloxacin-resistant isolates did not have *qnr* genes. Resistance in these isolates could be caused by other resistance mechanisms, which are noted in previous studies ([@A16217R33]).

In our study, some *E. coli* isolates possessed both ESBL and *qnr* genes. This could occur because of insertion into the same plasmid, which can be easily transmitted to other organisms and increase the number of multidrug-resistant isolates. The high prevalence of quinolone-resistant genes at Imam Reza Hospital of Mashhad indicates antibiotic resistance, which is a major concern. Hence, the antibiotics prescription policy should be revised, and infection control measures should be improved.
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